ReviewGut microbes2025
Metabolism of inositol derivatives by the gut microbiome.
Review in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Whole and Sprouted Cereals as Nutritional Modulators of the Gut Microbiota and Intestinal Inflammation in IBD.Nutrients · 2026Review
- Xylanase and phytase as modulators of gut microbiota and phytate degradation in wheat-based diets for meat quail.Poultry science · 2026Article
- Comparative Gut Microbiome Alterations in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID-19 Syndrome.Biomedicines · 2026Article
- Article
- Multi-omic stable isotope probing revealsISME communications · 2026Article
- The gut and circulating virome: emerging players in aging and longevity.Frontiers in aging · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome harbors immense metabolic capacity, much of which is still being uncovered. Recent discoveries have highlighted the ability of gut microbes to metabolize inositol-derived compounds, including free inositols and their phosphorylated derivatives, inositol phosphates. While these compounds are abundant in plant-based diets, our understanding of the specific bacterial taxa involved and their metabolic pathways has only recently begun to emerge. Intriguingly, inositols and inositol phosphates have been associated with a range of health benefits. Although some effects have been attributed to direct absorption or chemical interactions within the host, increasing evidence points to the gut microbiota as a key mediator in unlocking their therapeutic potential. This review emphasizes the microbial metabolism of inositol derivatives, highlights the intersection between diet, microbial function, and host health, and discusses their implications for nutrition and future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.